PSPeter Dieter Schellinger

Peter Dieter Schellinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter Dieter Schellinger has a total of 317 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Functional Outcomes and Safety of Endovascular Thrombectomy in Pediatric Acute Ischemic Stroke With Cardiac Abnormalities

    by Adam A. Dmytriw, Iman Kiani, Alireza Kooshki, Kartik D. Bhatia, Todd Abruzzo, Lisa Pabst, Stuart Fraser, Melissa Chung, Warren D. Lo, Ahmed Othmann, et al.

    Background and ObjectivesCardiac abnormalities are among the most common and complex risk factors of pediatric acute ischemic stroke (AIS). Although endovascular treatment (EVT) is increasingly use...

  • Open Access

    Synchronous Late-Onset of Limbic Encephalitis and Tumefactive Demyelinating Lesion After the End of Immunotherapy

    by Marcel Baehr, Peter D. Schellinger, Jan Borggrefe, Alexey Surov

    Immunoreactive encephalitis is a very rare side effect of immunotherapy, which can lead to severe morbidity. Following azetolizumab, it typically occurs within 0–12 months, with a median of 15 days. In this case, immunoreactive encephalitis occurred 3.5 months after treatment with azetolizumab ended and 15.5 months after it began. Tumefactive demyelinating lesions represent a focal cerebral lesion with inflammatory demyelination. They are usually associated with multiple sclerosis, but can also occur drug-induced or in the context of autoantibody-mediated diseases. In MRI, tumefactive demyelinating lesions mimic cerebral metastases. 18 F-FDG PET/CT can enhance the diagnostic precision of both immunoreactive encephalitis and tumefactive demyelinating lesions.

  • Endovascular Treatment in Acute Ischemic Stroke Due to Occlusion of Medium or Distal Vessels

    by Lina Palaiodimou, Apostolos Safouris, Nikolaos M. Papageorgiou, Konstantinos Melanis, George Magoufis, Aikaterini Theodorou, Stavros Spiliopoulos, Michael M. Mantatzis, Marios Themistocleous, Konstantinos Toutouzas, et al.

    Endovascular treatment (EVT) is the standard of care for acute ischemic stroke (AIS) due to large vessel occlusions, but its efficacy and safety in medium or distal vessel occlusions (MDVOs) remain uncertain. This systematic review and meta-analysis evaluated EVT plus best medical treatment (BMT) vs BMT alone in patients with MDVO-AIS. MEDLINE, Scopus, and ClinicalTrials.gov were searched through February 2025 for randomized-controlled clinical trial (RCT) data and observational evidence comparing EVT plus BMT vs BMT alone in adults with MDVO-AIS. The primary efficacy outcome was 3-month excellent functional outcome (modified Rankin Scale [mRS]-score 0-1), while good functional outcome (mRS score 0-2), reduced disability (mRS shift analysis), and pooled rates of successful recanalization were assessed as secondary outcomes. The primary safety outcome was symptomatic intracranial hemorrhage (sICH), while any ICH, 3-month all-cause mortality, and procedure-related complications were also evaluated. Thirty-eight studies (3 RCTs, 1 post hoc RCT analysis, 1 RCT individual patient data meta-analysis, and 33 observational studies) were included comprising 4,584 EVT-treated patients (mean age 71 years; 46% females) and 5,468 BMT-only patients (mean age 72; 46% females). Patients receiving EVT had similar rates of 3-month excellent functional outcome compared with BMT alone (risk ratio [RR] 1.02; 95% CI 0.93-1.12; p = 0.676; 30 studies; I2 = 67%). The 2 groups did not differ in good functional outcome (RR 1.00; 95% CI 0.94-1.07; p = 0.933; 36 studies; I2 = 71%) or reduced disability (common odds ratio 0.92; 95% CI 0.80-1.07; p = 0.290; 10 studies; I2 = 20%). The pooled rate of successful recanalization in the EVT arm was 78% (95% CI 75%-82%; 25 studies; I2 = 82%). EVT was associated with higher rates of sICH (RR 1.54; 95% CI 1.18-2.01; p = 0.002; 29 studies; I2 = 24%), any ICH (RR 1.62; 95% CI 1.38-1.92; p < 0.001; 17 studies; I2 = 40%), and 3-month all-cause mortality (RR 1.26; 95% CI 1.05-1.50; p = 0.012; 29 studies; I2 = 27%). The pooled rate of procedure-related complications was 8% (95% CI 5%-12%; 8 studies; I2 = 76%). No significant subgroup differences emerged when stratified for study design or NIH Stroke Scale strata. In this comprehensive synthesis of available evidence, EVT did not improve functional outcomes compared with BMT in MDVO-AIS, while it increased the risk of hemorrhagic complications and mortality. These findings argue against the routine use of EVT for MDVO-AIS. A key limitation is the predominance of observational data, underscoring the need for further RCTs to refine patient selection. The prespecified protocol of the present systematic review and meta-analysis has been registered in the International Prospective Register of Ongoing Systematic Reviews PROSPERO (registration ID: CRD42025651283).


  • Open Access

    European Stroke Organisation (ESO) standard operating procedure for white papers (expert consensus based clinical guidance)

    by Diana Aguiar de Sousa, Annaelle Zietz, Marialuisa Zedde, Aristeidis H Katsanos, Linxin Li, Joan Marti-Fabregas, Christian H Nolte, Anna Podlasek, Sven Poli, Jan Purrucker, et al.

    Promoting the highest quality, evidence-based research across Europe is a priority of the European Stroke Organisation (ESO). The ESO Guideline Board communicate and promote evidence-based recommendations for clinical practice through their Guidelines. However, there are many aspects of stroke care where robust scientific evidence may be unavailable or difficult to obtain. Thus, there is a need for practical, consensus guidance, produced following robust, consistent, and transparent methods, that is suitable for high-priority clinical scenarios where evidence is currently lacking. The ESO Guideline Board developed methods for producing practical clinical guidance based on expert consensus in response to this need. These ESO’ White Papers’ are intended to complement standard ESO Guidelines. Here, we outline the ESO White Papers’ standard operating procedure (SOP). We will describe the motivation for creating White Papers, the preferred composition of writing groups and expert consensus panellists, the methods for achieving consensus, and how results will be communicated. To ensure that all voting members have an equal voice, our methods are based upon the Delphi process of repeated rounds of anonymous voting, feedback and review. We hope that the White Papers will add further value to the clinical practice guidance that is offered by ESO. We look forward to receiving suggestions for White Paper topics from the stroke community.


  • Open Access

    Randomized controlled trials of endovascular therapy for acute ischemic stroke with medium or distal vessel occlusion: a study level metaanalysis

    by Peter D. Schellinger, Georgios Tsivgoulis, Benedikt Frank, Thomas Liebig, Martin Köhrmann

    Introduction: A decade ago, endovascular therapy (EVT) for acute ischemic stroke (AIS) with large vessel occlusion (LVO) has been established as standard of care. It is still a matter of debate whether EVT is better and safe for patients with more distal occlusions (DMVO). Three randomized controlled trials investigated the role of EVT on top of best medical treatment (BMT) for patients with DMVO. Methods: In a narrative review we present the results of 3 randomized controlled trials (RCT), (DISTAL, ESCAPE MeVO, DISCOUNT) of EVT plus BMT versus BMT alone. In addition, we performed a study level meta-analysis with a random-effects model for three endpoints: independent outcome, symptomatic intracranial hemorrhage (sICH) and death. Results: There was neither a significant effect of EVT plus BMT versus BMT alone on functional outcome (RR 0.92, 95% CI 0.80–1.06, p = 0.272), nor did the odds of death differ (OR 1.23, 95% CI 0.76–1.99, p = 0.409). The odds for sICH were more than twice as high with EVT (OR 2.38, 95% CI 1.35–4.20, p = 0.003). Conclusion: At present EVT for medium and distal vessel occlusions in AIS patients is not a standard of care. With equipoise for EVT in DMVO now an unbiased and rapid randomization into new and differently designed RCT should be a top priority.


  • Top Cited Papers

    Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours

    by Lina Palaiodimou, Aristeidis H. Katsanos, Guillaume Turc, Alexandros-Georgios Asimakopoulos, Dimitrios Mavridis, Peter D. Schellinger, Aikaterini Theodorou, Robin Lemmens, Simona Sacco, Apostolos Safouris, et al.

    The current European Stroke Organisation expedited recommendation on tenecteplase (TNK) for acute ischemic stroke (AIS) advocates that TNK 0.25 mg/kg can be used alternatively to alteplase (tissue plasminogen activator [TPA]) for AIS of p = 0.012; I2 = 0%; risk difference 2.95%; 95% CI 0.76%-5.14%; p = 0.008; I2 = 0%) and reduced disability at 3 months (common odds ratio 1.10, 95% CI 1.01-1.19; p = 0.034; I2 = 0%) compared with TPA while good functional outcome (RR 1.03, 95% CI 0.99-1.07; p = 0.142; I2 = 28%) was similar between the groups. Regarding safety outcomes, similar rates of sICH (RR 1.12, 95% CI 0.83-1.53; p = 0.456; I2 = 0%) and 3-month mortality (RR 0.97, 95% CI 0.82-1.15; p = 0.727; I2 = 12%) were observed. When stratified for TNK regimen (original vs biocopy), statistical significance in achieving an excellent functional outcome at 3 months was retained for the original TNK (RR 1.05, 95% CI 1.00-1.10; p = 0.044; I2 = 0%). The updated meta-analysis confirms similar safety between TNK 0.25 mg/kg and TPA, while showing that TNK is superior to TPA regarding excellent functional outcome and reduced disability at 3 months. These findings support transitioning to TNK in clinical practice.


  • Open Access

    Nerve cross‐sectional area from childhood to old age: A high‐resolution nerve ultrasound study

    by Jörg Philipps, Robin Denz, Melis Tahmaz, Ifirae Yusuf, Hannah Mork, Peter Dieter Schellinger, Anna Lena Fisse

    Background and purpose: Nerve cross‐sectional area (CSA) is not constant over the human lifespan. The relationship between an increasing CSA and age has been described as a linear positive correlation, but few studies have found a linear decrease in nerve size with older age. The aim of the present study was to analyze the development of nerve CSA in a healthy population from early childhood to old age using high‐resolution ultrasound.Methods: The median, ulnar, radial and sural nerves were examined bilaterally at 18 nerve sites in 110 healthy children, adolescents and adults aged between 2 and 98 years. The CSA of every nerve site was evaluated separately and in different age groups. The correlation of CSA with age, height and weight was analyzed in a linear, logarithmic and quadratic model and correlation coefficients were compared in a goodness‐of‐fit analysis. Models were then adjusted for weight and height.Results: Linear CSA–age correlations showed the lowest correlation coefficients for all nerve sites. An inverted parabolic curve suggesting a quadratic correlation of CSA and age was the best‐fitting model. Weight and height had a higher predictive value than age in adjusted models.Conclusions: There is an increase in nerve size during childhood and adolescence and a trend towards a decrease in old age, suggesting an inverted parabolic curve partly explained by age‐related changes in weight and height. Enlarged nerves in elderly individuals should not be attributed to age alone.


  • Distinguishing Transient Cerebral Ischemia From Other Brief Neurologic Events

    by Steven Warach, Peter D. Schellinger

    "Nam et ipsa scientia potestas est ['knowledge itself is power']." Sir Francis Bacon, Meditationes Sacrae (1597).


  • Open Access

    High‐resolution nerve ultrasound and corneal confocal microscopy in taxane‐induced polyneuropathy

    by Maria Katz, Hannah Mork, Nazik Baghdasaryan, Lukas Hesse, Kai Wille, Jasmin Treichel, Jeremias Motte, Rafael Klimas, Dietrich Sturm, Peter Dieter Schellinger, et al.

    Background and purpose: The role of high‐resolution nerve ultrasound (HRUS) and corneal confocal microscopy (CCM) in the early detection of taxane‐induced polyneuropathy (TIPN) is unclear. The present prospective longitudinal controlled observational pilot study estimates the role of HRUS and CCM in the early diagnosis of TIPN in breast cancer patients.Methods: Fifteen breast cancer patients receiving paclitaxel and 15 healthy age matched controls were included. Visits before and 3 weeks, 8 weeks and 6 months after treatment included clinical examination, the total neuropathy score, nerve conduction studies (NCS), monocular CCM including corneal nerve fibre length, density and branching and HRUS of bilateral median, ulnar, radial, tibial, peroneal and sural nerves. Patients were compared between different visits and to healthy controls.Results: Total neuropathy score increased from 2.2 at baseline to 5.8 (p < 0.001) at week 8. NCS showed a decreased sensory amplitude in the sural, radial, ulnar and median nerve after 6 months (p < 0.001). HRUS revealed a significant increase of cross‐sectional area in the sural nerve (p = 0.004), the median nerve (p = 0.003) at the carpal tunnel and the ulnar nerve in the forearm (p = 0.006) after 6 months. CCM showed no changes at different visits.Conclusions: Corneal confocal microscopy and HRUS do not detect early signs of TIPN during the paclitaxel treatment period. HRUS and NCS might detect congruent signs of an axonal, predominantly sensory polyneuropathy after 6 months. The clinical examination remains the most sensitive tool in the early detection of TIPN in breast cancer patients.


  • Sarcopenia is a predictor of patient death in acute ischemic stroke

    by Jan Boriesosdick, Alexey Surov, Arwed Michael, Christoph Mönninghoff, Julius Henning Niehoff, Nina Pauline Haag, Iram Shahzadi, Jan-Robert Kroeger, Peter Schellinger, Jan Borggrefe